GeoVax Labs (GOVX) 10-Q 5 Nov 20 2020 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 05, 2020
Document Information [Line Items]
Entity Registrant Name	GeoVax Labs, Inc.
Entity Central Index Key	0000832489
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		3,810,836
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
ASSETS
Cash and cash equivalents	$ 11,580,594	$ 283,341
Grant funds and other receivables	141,154	68,603
Prepaid expenses and other current assets	13,046	95,320
Total current assets	11,734,794	447,264
Property and equipment, net (Note 5)	10,093	10,606
Deposits	11,010	11,010
Total assets	11,755,897	468,880
Current liabilities:
Accounts payable	161,478	152,653
Accrued expenses (Note 6)	579,585	1,851,040
Current portion of notes payable	182,584	12,500
Total current liabilities	923,647	2,016,193
Note payable, net of current portion	18,506	27,243
Total liabilities	942,153	2,043,436
Commitments (Note 9)
Stockholders’ equity (deficiency):
Preferred Stock, $.01 par value (Note 10): Authorized shares – 10,000,000 Issued and outstanding shares – 400 and 2,486 June 30, 2020 and December 31, 2019, respectively	76,095	1,932,433
Common stock, $.001 par value: Authorized shares – 600,000,000 Issued and outstanding shares – 13,834,075 and 299,835 at June 30, 2020 and December 31, 2019, respectively	3,559	15
Additional paid-in capital	55,203,149	39,340,509
Accumulated deficit	(44,469,059)	(42,847,513)
Total stockholders’ equity (deficiency)	10,813,744	(1,574,556)
Total liabilities and stockholders’ equity (deficiency)	$ 11,755,897	$ 468,880

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	100	2,486
Preferred stock, shares outstanding (in shares)	100	2,486
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	600,000,000	600,000,000
Common stock, shares issued (in shares)	3,559,473	14,992
Common stock, shares outstanding (in shares)	3,559,473	14,992

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Grant and collaboration revenue	$ 415,458	$ 333,209	$ 1,572,037	$ 907,382
Operating expenses:
Research and development	416,756	467,674	1,687,113	1,474,619
General and administrative	435,013	291,475	1,364,650	1,214,189
Total operating expenses	851,769	759,149	3,051,763	2,688,808
Loss from operations	(436,311)	(425,940)	(1,479,726)	(1,781,426)
Other income (expense):
Interest income	90	2,560	902	4,665
Interest expense	(134,427)	(1,054)	(142,722)	(3,275)
Total other income (expense)	(134,337)	1,506	(141,820)	1,390
Net loss	$ (570,648)	$ (424,434)	$ (1,621,546)	$ (1,780,036)
Basic and diluted:
Net loss per common share (in dollars per share)	$ (0.73)	$ (1,282.28)	$ (2.85)	$ (14,016.03)
Weighted average shares outstanding (in shares)	782,978	331	569,955	127

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited) - USD ($)	Conversion from Convertible Debentures to Conversion Units [Member]Preferred Stock [Member]	Conversion from Convertible Debentures to Conversion Units [Member]Common Stock [Member]	Conversion from Convertible Debentures to Conversion Units [Member]Additional Paid-in Capital [Member]	Conversion from Convertible Debentures to Conversion Units [Member]Retained Earnings [Member]	Conversion from Convertible Debentures to Conversion Units [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2018						3,450	11
Balance at Dec. 31, 2018						$ 1,971,333		$ 37,483,204	$ (40,476,884)	$ (1,022,347)
Net loss									(701,454)	(701,454)
Balance at Mar. 31, 2019						$ 2,072,108		37,899,081	(41,178,338)	(1,207,149)
Balance (in shares) at Dec. 31, 2018						3,450	11
Balance at Dec. 31, 2018						$ 1,971,333		37,483,204	(40,476,884)	(1,022,347)
Net loss										(1,780,036)
Balance at Sep. 30, 2019						$ 2,321,823	$ 3	38,914,375	(42,256,920)	(1,020,719)
Balance (in shares) at Dec. 31, 2018						3,450	11
Balance at Dec. 31, 2018						$ 1,971,333		37,483,204	(40,476,884)	(1,022,347)
Sale of convertible preferred stock for cash and cancellation of note payable (in shares)						500
Sale of convertible preferred stock for cash and cancellation of note payable						$ 404,250		85,750		490,000
Conversion of preferred stock to common stock (in shares)						(767)	3
Conversion of preferred stock to common stock						$ (303,475)		303,475
Net loss
Balance at Mar. 31, 2020						$ 376,095	$ 690	41,202,172	(43,443,207)	(1,864,250)
Balance (in shares) at Mar. 31, 2019						3,183	14
Balance at Mar. 31, 2019						$ 2,072,108		37,899,081	(41,178,338)	(1,207,149)
Sale of convertible preferred stock for cash and cancellation of note payable (in shares)						500
Sale of convertible preferred stock for cash and cancellation of note payable						$ 438,700		61,300		500,000
Conversion of preferred stock to common stock (in shares)						(281)	6
Conversion of preferred stock to common stock						$ (172,941)		172,941
Common stock issued for services (in shares)
Common stock issued for services								6,000		6,000
Net loss									(654,148)	(654,148)
Balance at Jun. 30, 2019						$ 2,337,867		38,165,986	(41,832,486)	(1,328,633)
Balance (in shares) at Jun. 30, 2019						3,402	20
Sale of convertible preferred stock for cash and cancellation of note payable (in shares)						700
Sale of convertible preferred stock for cash and cancellation of note payable						$ 700,000				700,000
Conversion of preferred stock to common stock (in shares)						(1,048)	2,369
Conversion of preferred stock to common stock						$ (716,044)	$ 3	716,041
Common stock issued for services (in shares)							1
Common stock issued for services								6,000		6,000
Net loss									(424,434)	(424,434)
Balance at Sep. 30, 2019						$ 2,321,823	$ 3	38,914,375	(42,256,920)	(1,020,719)
Balance (in shares) at Dec. 31, 2019						2,486	14,992
Balance at Dec. 31, 2019						$ 1,932,433	$ 15	39,340,509	(42,847,513)	(1,574,556)
Sale of convertible preferred stock for cash and cancellation of note payable (in shares)						300
Sale of convertible preferred stock for cash and cancellation of note payable						$ 300,000				300,000
Conversion of preferred stock to common stock (in shares)						(2,386)	674,067
Conversion of preferred stock to common stock						$ (1,856,338)	$ 674	1,855,664
Common stock issued for services (in shares)							521
Common stock issued for services							$ 1	5,999		6,000
Net loss									(595,694)	(595,694)
Balance at Mar. 31, 2020						$ 376,095	$ 690	41,202,172	(43,443,207)	(1,864,250)
Balance (in shares) at Dec. 31, 2019						2,486	14,992
Balance at Dec. 31, 2019						$ 1,932,433	$ 15	39,340,509	(42,847,513)	$ (1,574,556)
Common stock issued for services (in shares)										3,162
Net loss										$ (1,621,546)
Stock Issued During Period, Shares, Warrants Exercised										36,902
Stock Issued During Period, Shares, Cancellation of Accrued Compensation										300,001
Balance at Sep. 30, 2020						$ 76,095	$ 3,559	55,203,149	(44,469,059)	$ 10,813,744
Balance (in shares) at Mar. 31, 2020						400	689,580
Balance at Mar. 31, 2020						$ 376,095	$ 690	41,202,172	(43,443,207)	(1,864,250)
Common stock issued for services (in shares)							2,124
Common stock issued for services							$ 2	11,998		12,000
Net loss									(455,204)	(455,204)
Warrants issued in bridge financing								457,833		457,833
Balance at Jun. 30, 2020						$ 376,095	$ 692	41,672,003	(43,898,411)	(1,849,621)
Balance (in shares) at Jun. 30, 2020						400	691,704
Conversion of preferred stock to common stock (in shares)		177,626				(300)	42,723
Conversion of preferred stock to common stock		$ 177	$ 569,340		$ 569,517	$ (300,000)	$ 43	299,957
Common stock issued for services (in shares)							517
Common stock issued for services								6,000		6,000
Net loss									(570,648)	(570,648)
Stock Issued During Period, Shares, Warrants Exercised							36,902
Warrants exercised for common stock							$ 37	(37)
Stock Issued During Period, Shares, Cancellation of Accrued Compensation							300,001
Common stock issued upon cancellation of accrued compensation							$ 300	1,499,700		1,500,000
Sale of common stock for cash (in shares)							2,310,000
Sale of common stock for cash							$ 2,310	11,156,186		11,158,496
Balance at Sep. 30, 2020						$ 76,095	$ 3,559	$ 55,203,149	$ (44,469,059)	$ 10,813,744

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2018	3,450	11
Balance at Dec. 31, 2018	$ 1,971,333		$ 37,483,204	$ (40,476,884)	$ (1,022,347)
Net loss				(701,454)	(701,454)
Balance (in shares) at Mar. 31, 2019	3,183	14
Balance at Mar. 31, 2019	$ 2,072,108		37,899,081	(41,178,338)	(1,207,149)
Balance (in shares) at Dec. 31, 2018	3,450	11
Balance at Dec. 31, 2018	$ 1,971,333		37,483,204	(40,476,884)	(1,022,347)
Net loss					(1,780,036)
Balance (in shares) at Sep. 30, 2019	3,054	2,390
Balance at Sep. 30, 2019	$ 2,321,823	$ 3	38,914,375	(42,256,920)	(1,020,719)
Balance (in shares) at Dec. 31, 2018	3,450	11
Balance at Dec. 31, 2018	$ 1,971,333		37,483,204	(40,476,884)	(1,022,347)
Sale of convertible preferred stock for cash and cancellation of note payable (in shares)	500
Sale of convertible preferred stock for cash and cancellation of note payable	$ 404,250		85,750		490,000
Conversion of preferred stock to common stock (in shares)	(767)	3
Conversion of preferred stock to common stock	$ (303,475)		303,475
Stock option expense			26,652		26,652
Net loss
Balance (in shares) at Mar. 31, 2020	400	689,580
Balance at Mar. 31, 2020	$ 376,095	$ 690	41,202,172	(43,443,207)	(1,864,250)
Balance (in shares) at Mar. 31, 2019	3,183	14
Balance at Mar. 31, 2019	$ 2,072,108		37,899,081	(41,178,338)	(1,207,149)
Sale of convertible preferred stock for cash and cancellation of note payable (in shares)	500
Sale of convertible preferred stock for cash and cancellation of note payable	$ 438,700		61,300		500,000
Conversion of preferred stock to common stock (in shares)	(281)	6
Conversion of preferred stock to common stock	$ (172,941)		172,941
Stock option expense			26,664		26,664
Net loss				(654,148)	(654,148)
Common stock issued for services (in shares)
Common stock issued for services			6,000		6,000
Balance (in shares) at Jun. 30, 2019	3,402	20
Balance at Jun. 30, 2019	$ 2,337,867		38,165,986	(41,832,486)	(1,328,633)
Sale of convertible preferred stock for cash and cancellation of note payable (in shares)	700
Sale of convertible preferred stock for cash and cancellation of note payable	$ 700,000				700,000
Conversion of preferred stock to common stock (in shares)	(1,048)	2,369
Conversion of preferred stock to common stock	$ (716,044)	$ 3	716,041
Stock option expense			26,348		26,348
Net loss				(424,434)	(424,434)
Common stock issued for services (in shares)		1
Common stock issued for services			6,000		6,000
Balance (in shares) at Sep. 30, 2019	3,054	2,390
Balance at Sep. 30, 2019	$ 2,321,823	$ 3	38,914,375	(42,256,920)	(1,020,719)
Balance (in shares) at Dec. 31, 2019	2,486	14,992
Balance at Dec. 31, 2019	$ 1,932,433	$ 15	39,340,509	(42,847,513)	(1,574,556)
Sale of convertible preferred stock for cash and cancellation of note payable (in shares)	300
Sale of convertible preferred stock for cash and cancellation of note payable	$ 300,000				300,000
Conversion of preferred stock to common stock (in shares)	(2,386)	674,067
Conversion of preferred stock to common stock	$ (1,856,338)	$ 674	1,855,664
Net loss				(595,694)	(595,694)
Common stock issued for services (in shares)		521
Common stock issued for services		$ 1	5,999		6,000
Balance (in shares) at Mar. 31, 2020	400	689,580
Balance at Mar. 31, 2020	$ 376,095	$ 690	41,202,172	(43,443,207)	(1,864,250)
Balance (in shares) at Dec. 31, 2019	2,486	14,992
Balance at Dec. 31, 2019	$ 1,932,433	$ 15	39,340,509	(42,847,513)	(1,574,556)
Net loss					$ (1,621,546)
Common stock issued for services (in shares)					3,162
Balance (in shares) at Sep. 30, 2020	100	3,559,473
Balance at Sep. 30, 2020	$ 76,095	$ 3,559	55,203,149	(44,469,059)	$ 10,813,744
Balance (in shares) at Mar. 31, 2020	400	689,580
Balance at Mar. 31, 2020	$ 376,095	$ 690	41,202,172	(43,443,207)	(1,864,250)
Net loss				(455,204)	(455,204)
Common stock issued for services (in shares)		2,124
Common stock issued for services		$ 2	11,998		12,000
Balance (in shares) at Jun. 30, 2020	400	691,704
Balance at Jun. 30, 2020	$ 376,095	$ 692	41,672,003	(43,898,411)	(1,849,621)
Conversion of preferred stock to common stock (in shares)	(300)	42,723
Conversion of preferred stock to common stock	$ (300,000)	$ 43	299,957
Net loss				(570,648)	(570,648)
Common stock issued for services (in shares)		517
Common stock issued for services			6,000		6,000
Balance (in shares) at Sep. 30, 2020	100	3,559,473
Balance at Sep. 30, 2020	$ 76,095	$ 3,559	$ 55,203,149	$ (44,469,059)	$ 10,813,744

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities:
Net loss	$ (1,621,546)	$ (1,780,036)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,983	5,693
Stock-based compensation expense	24,000	290,744
Changes in assets and liabilities:
Grant funds and other receivables	(72,551)	18,329
Prepaid expenses and other current assets	82,274	(83,637)
Amortization of debt discount	124,185
Accounts payable and accrued expenses	252,036	431,170
Total adjustments	412,927	662,299
Net cash used in operating activities	(1,208,619)	(1,117,737)
Cash flows from investing activities:
Purchase of property and equipment	(2,470)	(4,272)
Net cash used in investing activities	(2,470)	(4,272)
Cash flows from financing activities:
Net proceeds from sale of preferred stock	300,000	1,440,000
Net proceeds from issuance of note payable	170,200
Net proceeds from bridge financing	888,500
Net proceeds from sale of common stock and warrants	11,158,496
Principal repayment of note payable	(8,854)	(8,333)
Net cash provided by financing activities	12,508,342	1,431,667
Net increase in cash and cash equivalents	11,297,253	309,658
Cash and cash equivalents at beginning of period	283,341	259,701
Cash and cash equivalents at end of period	$ 11,580,594	$ 569,359

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cancellation of deferred compensation liability	$ 1,500,000
Stock Issued During Period, Shares, Cancellation of Accrued Compensation	300,001
Stock Issued During Period, Shares, Warrants Exercised	36,902
Conversion of Series H, Series I, and Series J Preferred Stock into Common Stock [Member]
Common stock issued upon conversion of preferred stock (in shares)	716,790	2,378
Series G Convertible Preferred Stock Issued in Exchange for Cancellation of Term notes Payable [Member]
Original amount converted in debt conversion		$ 250,000
Stock issued in conversion of debt (in shares)		250
Unit Warrants [Member]
Unit warrants issued (in shares)	300,001
Conversion from Convertible Debentures to Conversion Units [Member]
Accrued interest converted in debt conversion	$ 14,667
Original amount converted in debt conversion	$ 1,200,000
Stock issued in conversion of debt (in shares)	177,626
Conversion from Convertible Debentures to Conversion Units [Member] | Unit Warrants [Member]
Warrants issued in debt conversion (in shares)	303,668
Conversion from Convertible Debentures to Conversion Units [Member] | Pre-Funded Warrants [Member]
Warrants issued in debt conversion (in shares)	126,042

Note 1 - Description of Busines

Note 1 - Description of Business	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Nature of Operations [Text Block]	1. Description of Business GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers using a novel vector vaccine platform (Modified Vaccinia Ankara (MVA) Virus-Like Particle, or “GV-MVA-VLP TM Our current development programs are focused on preventive vaccines against novel coronavirus (COVID- 19 Our corporate strategy is to advance, protect and exploit our differentiated vaccine immunotherapy platform leading to the successful development of preventive and therapeutic vaccines against infectious diseases and various cancers. With our design and development capabilities, we are progressing and validating an array of cancer and infectious disease immunotherapy and vaccine product candidates. Our goal is to advance products through to human clinical testing, and to seek partnership or licensing arrangements for achieving regulatory approval and commercialization. We also leverage third Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. Government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials. We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may one GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area.

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Basis of Accounting [Text Block]	2. Basis of Presentation The accompanying condensed consolidated financial statements at September 30, 2020 three nine September 30, 2020 2019 not 10 December 31, 2019. not As described in Note 10, April 30, 2019, January 21, 2020 September 30, 2020. Our financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve For the last several years the audit reports to our consolidated financial statements have included a “going concern” qualification, arising from our limited assets, our history of operating losses, and our continuing need for capital to conduct our research and development activities. These conditions continued through the second 2020. third 2020 10 September 30, 2020 no twelve 2022. We expect to incur future net losses as we continue to fund the development of our product candidates. To date, we have financed our operations primarily with proceeds from sales of equity and debt securities, government grants and clinical trial assistance, and corporate collaborations. Our transition to profitability will be dependent upon, among other things, the successful development and commercialization of our product candidates. We may may no

Note 3 - Significant Accounting

Note 3 - Significant Accounting Policies and Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. Significant Accounting Policies and Recent Accounting Pronouncements We disclosed in Note 2 10 December 31, 2019 no 10 There have been no nine September 30, 2020, 10 December 31, 2019,

Note 4 - Basic and Diluted Loss

Note 4 - Basic and Diluted Loss Per Common Share	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	4. Basic and Diluted Loss Per Common Share Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share, totaled 204,553 78,754 three nine September 30, 2020, 273 272 three nine September 30, 2019, 10 September 30, 2020

Note 5 - Property and Equipment

Note 5 - Property and Equipment	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property and Equipment Property and equipment as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of September 30, 2020 December 31, 2019: September 30, 2020 December 31, 2019 Laboratory equipment $ 537,047 $ 534,577 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 11,736 11,736 Total property and equipment 664,388 661,918 Accumulated depreciation and amortization (654,295 ) (651,312 ) Property and equipment, net $ 10,093 $ 10,606

Note 6 - Accrued Expenses

Note 6 - Accrued Expenses	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6. Accrued Expenses Accrued expenses as shown on the accompanying Condensed Consolidated Balance Sheets are composed of the following as of September 30, 2020 December 31, 2019: September 30, 2020 December 31, 2019 Accrued payroll and director fees $ 551,762 $ 1,732,702 Other accrued expenses 27,823 118,338 Total accrued expenses $ 579,585 $ 1,851,040

Note 7 - Notes Payable

Note 7 - Notes Payable	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	7. Notes Payable GRA Note – February 28, 2018, five $50,000. 5%, $3,026 2020, $12,487 2021, $13,126 2022, $2,252 2023. three nine September 30, 2020 $411 $1,344, $547 $1,753, 2019. CARES Act Paycheck Protection Program Loan – April 17, 2020, $170,200 one April 17, 2022. November 17, 2020, $9,578.16 may $429 $774 three nine September 30, 2020, October 2020, not

Note 8 - Convertible Debentures

Note 8 - Convertible Debentures	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Short-term Debt [Text Block]	8. Convertible Debentures On June 26 2020, two $1,050,000 5% $1,200,000; five “June 2020 120,000 $10.00 $888,500. 10, September 29, 2020 June 2020 $5.00. twelve 5% The Convertible Debentures were mandatorily convertible upon our consummation of a public offering of common stock with gross proceeds of $6,000,000 $10.00 80% not 4.99% On September 29, 2020, 10, $1,200,000 $14,667 $4.00, 303,667 303,668 177,626 one a one 126,042 one one a one $0.01 not one $5.00 five Upon the issuance of the Convertible Debentures, we recorded a debt discount of $769,334, $150,000 $457,834 $161,500 12 September 29, 2020, $645,150 $133,148 138,851 three nine September 30, 2020, $119,139 $124,184,

Note 9 - Commitments

Note 9 - Commitments	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Commitments Disclosure [Text Block]	9. Commitments Lease Agreement -- 8,400 December 31, 2022. three nine September 30, 2020 $41,539 $124,617, $40,316 $120,949, 2019. $41,539 2020, $171,213 2021 $176,356 2022, may ninety Other Commitments – September 30, 2020, $290,500 $228,000 2020 $62,500 2021.

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Preferred Stock [Text Block]	10. Stockholders' Equity Convertible Preferred Stock We are authorized to issue up to 10,000,000 $.01 may one September 30, 2020 December 31, 2019. $1,000 nine September 30, 2020 September 30, 2020 December 31, 2019 Carrying Carrying Shares Value Shares Value Series B Convertible Preferred Stock 100 $ 76,095 100 $ 76,095 Series H Convertible Preferred Stock - - 1,686 1,156,338 Series I Convertible Preferred Stock - - 700 700,000 Total 100 $ 76,095 2,486 $ 1,932,433 As of September 30, 2020, 100 no nine September 30, 2020. During the first 2020, 1,686 469,696 September 30, 2020, no During the first 2020, 700 204,371 September 30, 2020, no On January 24, 2020, 300 $300,000. no not July 2020, 300 42,723 September 30, 2020, no Common Stock Reverse Stock Split s – April 30, 2019, 1 500 January 21, 2020, 1 2000 September 25, 2020, 1 20 Conversions of Preferred Stock nine September 30, 2020, 716,790 Public Offering – September 24, 2020, 2,560,000 September 29, 2020, $12.8 $11.2 Of the 2,560,000 2,310,000 one a one 250,000 a one a one $0.01 not one $5.00 five $5.00 $4.99 45 384,000 Pursuant to the Underwriting Agreement, we issued to the Representative, as a portion of the underwriting compensation, warrants to purchase up to a total of 128,000 $5.50 180 three Conversion of Deferred Compensation to Equity – 2016 2017, September 29, 2020, $1,500,000 $5.00 300,001 one one Conversion of Convertible Debentures to Equity 8, 177,625 126,042 303,667 $1,214,667 Other Common Stock Transactions – nine September 30, 2020, 3,162 Stock Options As a result of the reverse stock splits of our common stock all of our outstanding stock options were automatically adjusted such that all of such stock options as of the beginning of 2020 June 19, 2020, 2020 “2020 250,000 2020 No 2020 nine September 30, 2020. Stock Purchase Warrants Series G Warrants August 2020, no September 30, 2020. Series H Warrants July 2020, 7,147 no September 30, 2020. Series I Warrants July 2020, 29,755 September 30, 2020, 62,626 $5.00 June 2020 8, June 26, 2020, 120,000 five $10.00. September 29, 2020 $5.00. Warrants Issued Upon Conversion of Convertible Debentures 8, September 29, 2020, 126,042 303,668 Warrants Issued Upon Conversion of Deferred Compensation Common Stock – Conversion of Deferred Compensation to Equity September 29, 2020, 300,001 Warrants Issued in Connection with Public Offering Common Stock – Public Offering September 29, 2020, 2,560,000 250,000 128,000 Summary of Warrants Ou tst anding September 30, 2020: Warrant Description Number of Shares Exercise Price Expiration Series I Warrants 62,626 $ 5.00 Oct-Dec 2024 June 2020 Warrants 120,000 5.00 Jun 2025 Pre-Funded Warrants 376,042 0.01 Perpetual Unit, Conversion and Management Warrants 3,163,669 5.00 Sep 2025 Representative Warrants 128,000 5.50 Mar 2024 Total Warrants Outstanding at September 30, 2020 3,850,337 Weighted-Average Exercise Price $ 4.53 Weighted-Average Remaining Life (excluding Pre-Funded Warrants)(in years) 4.9 Stock-Based Compensation Expense There was no three nine September 30, 2020 no September 30, 2020. three nine September 30, 2020 $6,000 $24,000,

Note 11 - Income Taxes

Note 11 - Income Taxes	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	11. Income Taxes Because of our historically significant net operating losses, we have not 382

Note 12 - Grants and Collaborat

Note 12 - Grants and Collaboration Revenue	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Government Grants and Contracts [Text Block]	12. Grant and Collaboration Revenue We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During the three nine September 30, 2020, $231,330 $1,186,844, $214,765 $754,022, 2019. September 30, 2020, $417,121 September 2021. During the three nine September 30, 2020, $184,127 $385,193, third $118,444 $153,360, 2019.

Note 13 - Subsequent Events

Note 13 - Subsequent Events	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	13. Subsequent Events During October 2020, 250,000 250,000 $2,500.

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Property, Plant and Equipment [Table Text Block]	September 30, 2020 December 31, 2019 Laboratory equipment $ 537,047 $ 534,577 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 11,736 11,736 Total property and equipment 664,388 661,918 Accumulated depreciation and amortization (654,295 ) (651,312 ) Property and equipment, net $ 10,093 $ 10,606

Note 6 - Accrued Expenses (Tabl

Note 6 - Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	September 30, 2020 December 31, 2019 Accrued payroll and director fees $ 551,762 $ 1,732,702 Other accrued expenses 27,823 118,338 Total accrued expenses $ 579,585 $ 1,851,040

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Preferred Stock [Table Text Block]	September 30, 2020 December 31, 2019 Carrying Carrying Shares Value Shares Value Series B Convertible Preferred Stock 100 $ 76,095 100 $ 76,095 Series H Convertible Preferred Stock - - 1,686 1,156,338 Series I Convertible Preferred Stock - - 700 700,000 Total 100 $ 76,095 2,486 $ 1,932,433
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrant Description Number of Shares Exercise Price Expiration Series I Warrants 62,626 $ 5.00 Oct-Dec 2024 June 2020 Warrants 120,000 5.00 Jun 2025 Pre-Funded Warrants 376,042 0.01 Perpetual Unit, Conversion and Management Warrants 3,163,669 5.00 Sep 2025 Representative Warrants 128,000 5.50 Mar 2024 Total Warrants Outstanding at September 30, 2020 3,850,337 Weighted-Average Exercise Price $ 4.53 Weighted-Average Remaining Life (excluding Pre-Funded Warrants)(in years) 4.9

Note 4 - Basic and Diluted Lo_2

Note 4 - Basic and Diluted Loss Per Common Share (Details Textual) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	204,553	273	78,754	272

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Property and equipment, gross	$ 664,388	$ 661,918
Accumulated depreciation and amortization	(654,295)	(651,312)
Property and equipment, net	10,093	10,606
Laboratory Equipment [Member]
Property and equipment, gross	537,047	534,577
Leasehold Improvements [Member]
Property and equipment, gross	115,605	115,605
Other Furniture Fixtures And Equipment [Member]
Property and equipment, gross	$ 11,736	$ 11,736

Note 6 - Accrued Expenses - Sch

Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Accrued payroll and director fees	$ 551,762	$ 1,732,702
Other accrued expenses	27,823	118,338
Total accrued expenses	$ 579,585	$ 1,851,040

Note 7 - Notes Payable (Details

Note 7 - Notes Payable (Details Textual) - USD ($)	Apr. 17, 2020	Feb. 28, 2018	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Proceeds from Notes Payable, Total					$ 170,200
Long-Term Debt, Maturity, Year One			$ 3,026		3,026
Paycheck Protection Program CARES Act [Member]
Proceeds from Notes Payable, Total	$ 170,200
Interest Expense, Debt, Total			429		774
Debt Instrument, Periodic Payment, Total	$ 9,578.16
Senior Notes [Member]
Proceeds from Notes Payable, Total		$ 50,000
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Long-Term Debt, Maturity, Year One			12,487		12,487
Long-Term Debt, Maturity, Year Two			13,126		13,126
Long-Term Debt, Maturity, Year Three			2,252		2,252
Interest Expense, Debt, Total			$ 411	$ 547	$ 1,344	$ 1,753

Note 8 - Convertible Debentur_2

Note 8 - Convertible Debentures (Details Textual) - USD ($)	Sep. 29, 2020	Jun. 26, 2020	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 24, 2020
Proceeds from Convertible Debt				$ 888,500
Number of Common Stock Securities Called by Each Unit (in shares)	1
Amortization of Debt Discount (Premium)				124,185
Conversion from Convertible Debentures to Conversion Units [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 4
Debt Conversion, Original Debt, Amount	$ 1,200,000			1,200,000
Debt Conversion, Accrued Interest Amount	$ 14,667			$ 14,667
Debt Conversion, Converted Instrument, Shares Issued (in shares)	303,667			177,626
Conversion from Convertible Debentures to Conversion Units [Member] | Conversion Units Tranche One [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)	177,626
Number of Common Stock Securities Called by Each Unit (in shares)	1
Conversion from Convertible Debentures to Conversion Units [Member] | Conversion Units Tranche Two [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)	126,042
June 2020 Warrants [Member]
Warrants and Rights Outstanding, Term (Year)		5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		120,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 5	$ 10	$ 5	$ 5
Warrants and Rights Outstanding		$ 457,834
Payments of Debt Issuance Costs		$ 161,500
Conversion Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member] | Conversion Units Tranche One [Member]
Number of Warrants Called by Each Unit (in shares)	1
Conversion Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member] | Conversion Units Tranche Two [Member]
Number of Warrants Called by Each Unit (in shares)	1
Conversion Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1
Pre-Funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	250,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.01		$ 0.01	$ 0.01		$ 0.01
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1					1
Pre-Funded Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member] | Conversion Units Tranche Two [Member]
Number of Warrants Called by Each Unit (in shares)	1
Unit Warrants [Member]
Warrants and Rights Outstanding, Term (Year)	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	2,560,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 5
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1
Convertible Debentures [Member]
Number of Institutional Investors		2
Proceeds from Convertible Debt, Gross		$ 1,050,000
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Debt Instrument, Face Amount		$ 1,200,000
Proceeds from Convertible Debt		$ 888,500
Debt Instrument, Term (Month)		1 year
Gross Proceeds from Issuance of Common Stock, Public Offering		$ 6,000,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 10
Percentage of Offering Price		80.00%
Debt Instrument, Convertible, Maximum Allowed Ownership of Common Stock Outstanding, Percentage		4.99%
Debt Instrument, Unamortized Discount, Total	$ 645,150	$ 769,334
Debt Conversion, Original Debt Discount		$ 150,000
Interest Expense, Debt, Total			$ 133,148	$ 138,851
Amortization of Debt Discount (Premium)			$ 119,139	$ 124,184

Note 9 - Commitments (Details T

Note 9 - Commitments (Details Textual)	3 Months Ended		9 Months Ended
	Sep. 30, 2020USD ($)ft²	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)ft²	Sep. 30, 2019USD ($)
Area of Real Estate Property (Square Foot) | ft²	8,400		8,400
Operating Leases, Rent Expense, Total	$ 41,539	$ 40,316	$ 124,617	$ 120,949
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year	41,539		41,539
Lessee, Operating Lease, Liability, to be Paid, Year One	171,213		171,213
Lessee, Operating Lease, Liability, to be Paid, Year Two	176,356		176,356
Unrecorded Unconditional Purchase Obligation, Total	290,500		290,500
Purchase Obligation, to be Paid, Remainder of Fiscal Year	228,000		228,000
Purchase Obligation, to be Paid, Year One	$ 62,500		$ 62,500

Note 10 - Stockholders' Equit_2

Note 10 - Stockholders' Equity (Details Textual)	Sep. 29, 2020USD ($)$ / sharesshares	Sep. 25, 2020	Sep. 24, 2020USD ($)$ / sharesshares	Jan. 24, 2020USD ($)shares	Jan. 21, 2020	Apr. 30, 2019	Jul. 31, 2020shares	Sep. 30, 2020USD ($)$ / sharesshares	Mar. 31, 2020shares	Sep. 30, 2020USD ($)$ / sharesshares	Sep. 30, 2019shares	Jun. 26, 2020$ / sharesshares	Dec. 31, 2019$ / sharesshares
Preferred Stock, Shares Authorized (in shares)								10,000,000		10,000,000			10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares								$ 0.01		$ 0.01			$ 0.01
Preferred Stock, Shares Outstanding, Ending Balance (in shares)								100		100			2,486
Proceeds from Issuance or Sale of Equity, Gross | $			$ 12,800,000
Proceeds from Issuance or Sale of Equity, Total | $			$ 11,200,000
Number of Common Stock Securities Called by Each Unit (in shares)	1
Deferred Compensation Liability Conversion to Equity, Amount | $	$ 1,500,000									$ 1,500,000
Deferred Compensation Liability Conversion to Equity, Conversion Price (in dollars per share) | $ / shares	$ 5
Stock Issued During Period, Shares, Cancellation of Accrued Compensation (in shares)	300,001									300,001
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)	177,625
Stock Issued During Period, Shares, Issued for Services (in shares)										3,162
Class of Warrant or Right, Outstanding (in shares)								3,850,337		3,850,337
Stock Issued During Period, Shares, Warrants Exercised (in shares)										36,902
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $								$ 0		$ 0
Stock Issued During Period, Value Expensed During the Period, Issued for Services | $								6,000		24,000
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense | $								$ 0		$ 0
Stock Incentive Plan 2020 [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)								250,000		250,000
Conversion from Convertible Debentures to Conversion Units [Member]
Debt Conversion, Converted Instrument, Principal and Interest, Amount | $	$ 1,214,667
Representative [Member]
Over-Allotment Option, Term (Day)			45 days
Number of Units Granted for Over-Allotment (in shares)			384,000
Capital Units [Member]
Stock Issued During Period, Shares, New Issues (in shares)			2,560,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares			$ 5
Conversion Warrants [Member]
Class Of Warrant Or Right, Issued During Period (in shares)			2,560,000
Conversion Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member]
Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares)	303,667
Unit Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)			1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 5
Warrants and Rights Outstanding, Term (Year)			5 years
Pre-Funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1		1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 0.01		$ 0.01					$ 0.01		$ 0.01
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	250,000
Class of Warrant or Right, Outstanding (in shares)								376,042		376,042
Pre-Funded Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member]
Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares)	126,042									126,042
Representative Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 5.50					$ 5.5		$ 5.5
Warrants and Rights Outstanding, Term (Year)			3 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	128,000		128,000
Class of Warrant or Right, Period for Warrants or Rights Exercisable (Day)			180 days
Class of Warrant or Right, Outstanding (in shares)								128,000		128,000
Management Warrant [Member]
Number of Warrants Called by Each Unit (in shares)	1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	300,001
Series G Warrants [Member]
Class of Warrant or Right, Outstanding (in shares)								0		0
Series H Warrants [Member]
Class of Warrant or Right, Outstanding (in shares)								0		0
Stock Issued During Period, Shares, Warrants Exercised (in shares)							7,147
Series I Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares								$ 5		$ 5
Class of Warrant or Right, Outstanding (in shares)								62,626		62,626
Stock Issued During Period, Shares, Warrants Exercised (in shares)							29,755
June 2020 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 5							$ 5		$ 5		$ 10
Warrants and Rights Outstanding, Term (Year)												5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)												120,000
Class of Warrant or Right, Outstanding (in shares)								120,000		120,000
Unit Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 5
Warrants and Rights Outstanding, Term (Year)	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	2,560,000
Unit Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member]
Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares)										303,668
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		20			2,000	500
Conversion of Series H Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)									1,686
Conversion of Stock, Shares Issued (in shares)									469,696
Conversion of Series I Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)									700
Conversion of Stock, Shares Issued (in shares)									204,371
Conversion of Series J Preferred Stock into Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)							300
Conversion of Stock, Shares Issued (in shares)							42,723
Conversion of Series H, Series I, and Series J Preferred Stock into Common Stock [Member]
Conversion of Stock, Shares Issued (in shares)										716,790	2,378
Series B Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares								$ 1,000		$ 1,000			$ 1,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)								100		100			100
Series H Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)								0		0			1,686
Series I Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)								0		0			700
Series J Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)								0		0
Stock Issued During Period, Shares, New Issues (in shares)				300
Proceeds from Issuance of Preferred Stock and Preference Stock | $				$ 300,000
Capital Units Tranche One [Member] | Capital Units [Member]
Stock Issued During Period, Shares, New Issues (in shares)			2,310,000
Number of Common Stock Securities Called by Each Unit (in shares)			1
Capital Units Tranche One [Member] | Unit Warrant [Member] | Capital Units [Member]
Number of Warrants Called by Each Unit (in shares)			1
Capital Units Tranche Two [Member] | Capital Units [Member]
Stock Issued During Period, Shares, New Issues (in shares)			250,000
Capital Units Tranche Two [Member] | Unit Warrant [Member] | Capital Units [Member]
Number of Warrants Called by Each Unit (in shares)			1
Capital Units Tranche Two [Member] | Pre-Funded Warrants [Member] | Capital Units [Member]
Number of Warrants Called by Each Unit (in shares)			1
Units Including Pre-Funded Warrants [Member] | Capital Units [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares			$ 4.99

Note 10 - Stockholders' Equit_3

Note 10 - Stockholders' Equity - Preferred Stock Summary (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Preferred stock, shares outstanding (in shares)	100	2,486
Preferred Stock	$ 76,095	$ 1,932,433
Series B Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares)	100	100
Preferred Stock	$ 76,095	$ 76,095
Series H Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares)	0	1,686
Preferred Stock		$ 1,156,338
Series I Convertible Preferred Stock [Member]
Preferred stock, shares outstanding (in shares)	0	700
Preferred Stock		$ 700,000

Note 10 - Stockholders' Equit_4

Note 10 - Stockholders' Equity - Summary of Warrants (Details) - $ / shares	Sep. 30, 2020	Sep. 29, 2020	Sep. 24, 2020	Jun. 26, 2020
Number of warrants (in shares)	3,850,337
Weighted Average [Member]
Exercise price (in dollars per share)	$ 4.53
Series I Warrants [Member]
Number of warrants (in shares)	62,626
Exercise price (in dollars per share)	$ 5
June 2020 Warrants [Member]
Number of warrants (in shares)	120,000
Exercise price (in dollars per share)	$ 5	$ 5		$ 10
Weighted-Average Remaining Life (excluding Pre-Funded Warrants)(in years) (Year)				5 years
Pre-Funded Warrants [Member]
Number of warrants (in shares)	376,042
Exercise price (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Unit, Conversion and Management Warrants [Member]
Number of warrants (in shares)	3,163,669
Exercise price (in dollars per share)	$ 5
Representative Warrants [Member]
Number of warrants (in shares)	128,000
Exercise price (in dollars per share)	$ 5.5		$ 5.50
Weighted-Average Remaining Life (excluding Pre-Funded Warrants)(in years) (Year)			3 years
Outstanding Warrants Excluding Pre-Funded Warrants [Member] | Weighted Average [Member]
Weighted-Average Remaining Life (excluding Pre-Funded Warrants)(in years) (Year)	4 years 328 days

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details Textual) $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)
Income Taxes Paid	$ 0

Note 12 - Grants and Collabor_2

Note 12 - Grants and Collaboration Revenue (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue from Contract with Customer, Including Assessed Tax	$ 415,458	$ 333,209	$ 1,572,037	$ 907,382
Unused Grant Funds	417,121		417,121
NIH Grants [Member]
Revenue from Contract with Customer, Including Assessed Tax	231,330	214,765	1,186,844	754,022
Research Agreements [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 184,127	$ 118,444	$ 385,193	$ 153,360

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Oct. 31, 2020	Sep. 30, 2020	Sep. 30, 2020
Stock Issued During Period, Shares, Warrants Exercised (in shares)			36,902
Stock Issued During Period, Value, Warrants Exercised
Stock Issued During Period, Value, New Issues		$ 11,158,496
Subsequent Event [Member]
Stock Issued During Period, Value, Warrants Exercised	$ 250,000
Stock Issued During Period, Value, New Issues	$ 2,500
Subsequent Event [Member] | Pre-Funded Warrants [Member]
Stock Issued During Period, Shares, Warrants Exercised (in shares)	250,000